|
gptkbp:instanceOf
|
asset management company
|
|
gptkbp:assetsUnderManagement
|
gptkb:Novo_Nordisk_Foundation
|
|
gptkbp:AUM
|
over €100 billion
|
|
gptkbp:businessModel
|
private
|
|
gptkbp:CEO
|
gptkb:Kasim_Kutay
|
|
gptkbp:country
|
gptkb:Denmark
|
|
gptkbp:focusesOn
|
private equity
venture capital
public equity
seed investments
growth equity
life science investments
|
|
gptkbp:foundedBy
|
gptkb:Novo_Nordisk_Foundation
|
|
gptkbp:foundedIn
|
1999
|
|
gptkbp:headquartersLocation
|
gptkb:Copenhagen
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Novo Holdings
|
|
gptkbp:industry
|
life sciences
investment management
|
|
gptkbp:keyPerson
|
gptkb:Kasim_Kutay
|
|
gptkbp:legalForm
|
Aktieselskab (A/S)
|
|
gptkbp:notableInvestment
|
gptkb:Chr._Hansen
gptkb:Novozymes
gptkb:Visterra
gptkb:Novo_Nordisk
gptkb:Amolyt_Pharma
gptkb:Arvelle_Therapeutics
gptkb:Evaxion_Biotech
gptkb:NBE-Therapeutics
gptkb:Protera
gptkb:ReViral
gptkb:Xellia_Pharmaceuticals
gptkb:Convatec
gptkb:Evotec
gptkb:Orchard_Therapeutics
gptkb:CureVac
gptkb:Corvidia_Therapeutics
|
|
gptkbp:numberOfEmployees
|
over 100
|
|
gptkbp:parentOrganization
|
gptkb:Novo_Nordisk_Foundation
|
|
gptkbp:regionServed
|
global
|
|
gptkbp:subsidiary
|
gptkb:Novo_Nordisk_Foundation
|
|
gptkbp:website
|
https://www.novoholdings.dk/
|
|
gptkbp:bfsParent
|
gptkb:Tarveda_Therapeutics
|
|
gptkbp:bfsLayer
|
6
|